FDA Issues Co-Development Guidance, But Only For Products Treating "Serious" Diseases
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA Commissioner Hamburg and CDER Director Woodcock outline the requirements for developing drugs in combination during the Faster Cures Partnering for Cures meeting in New York.
You may also be interested in...
Co-Development Guidance Gives More Attention To IND, NDA/BLA Submissions
In a final guidance on co-development of two or more investigational new drugs for use in combination, FDA lays out general principles for IND and marketing application submissions, a topic on which the agency essentially punted in a December 2010 draft document.
Bill Proposes Offering Exclusivity For Novel Drug Co-Development
Bill proposes six months’ extra marketing exclusivity to spur development of combinations of investigational drugs for serious diseases. Setting aside prospects for passage in an election season, the question is whether that will be enough to get pharma to buy into a risky development space and pioneer a new business model.
Right Dosing, Scheduling Key To Anticipating Resistance, Creating Synergistic Combos In Drug Development
The art of developing synergistic combinations of novel drugs that can win the race against resistance mutations was much discussed at the American Association for Cancer Research meeting in Chicago March 31 - April 4.